Hydroxamic acids: proton donor and acceptor strength for use in drug design
- 10 October 2003
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 33 (4) , 783-788
- https://doi.org/10.1016/s0731-7085(03)00282-6
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokinesProceedings of the National Academy of Sciences, 2002
- Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancerInternational Journal of Cancer, 2001
- Comparison between deferoxamine and deferiprone (L1) in iron‐loaded thalassemia patientsEuropean Journal of Haematology, 2001
- Protection of outer hair cells from reperfusion injury by an iron chelator and a nitric oxide synthase inhibitor in the guinea pig cochleaNeuroscience Letters, 2001
- Protease Inhibitors: Synthesis of a Series of Bacterial Collagenase Inhibitors of the Sulfonyl Amino Acyl Hydroxamate TypeJournal of Medicinal Chemistry, 2001
- Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase InhibitorAntimicrobial Agents and Chemotherapy, 2001
- Antibacterial Agents That Target Lipid A Biosynthesis in Gram-negative BacteriaJournal of Biological Chemistry, 2000
- Antimalarial Activities of Polyhydroxyphenyl and Hydroxamic Acid DerivativesAntimicrobial Agents and Chemotherapy, 1998
- Antibacterial Agents That Inhibit Lipid A BiosynthesisScience, 1996
- Hydroxamic Acids in NatureScience, 1967